Composition of matter patent issued with coverage until June 2043

2043年6月前发布的物质专利组成

Patent also includes methods of use and methods of manufacturing claims

专利还包括使用方法和制造权利要求的方法

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 (“the ‘669 patent”) for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor (FcRn).

2024年3月12日，纽约（环球通讯社）--Immunovant，Inc.（纳斯达克：IMVT），一家致力于为自身免疫性疾病患者提供正常生活的临床阶段免疫学公司，今天宣布，美国专利商标局已为IMVT-1402颁发了第11926669号美国专利（“669专利”），该公司针对新生儿片段可结晶受体（FcRn）的第二代抗体。

The allowed claims cover composition of matter for the binding sequence of IMVT-1402 to FcRn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. Not including any potential patent term extension, the ‘669 patent will expire on June 23, 2043. IMVT-1402 is being developed by Immunovant based on antibody discovery efforts by HanAll Biopharma..

允许的权利要求涵盖IMVT-1402与FcRn结合序列的物质组成，用于治疗自身免疫性疾病的抗体的使用方法以及其制造方法。不包括任何潜在的专利期限延长，669年专利将于2043年6月23日到期。IMVT-1402是由Immunovant根据HanAll Biopharma的抗体发现工作开发的。。

IMVT-1402 delivered subcutaneously has demonstrated potentially best-in-class profile in a Phase 1 clinical trial in healthy adults, with initial data demonstrating a deep immunoglobulin G (IgG) reduction that is similar to batoclimab, but with no or minimal changes in serum albumin and LDL cholesterol, consistent with placebo.

在健康成年人的1期临床试验中，皮下递送的IMVT-1402已显示出潜在的最佳水平，初步数据显示免疫球蛋白G（IgG）的深度降低与巴托利马相似，但血清白蛋白和低密度脂蛋白胆固醇没有或变化很小，与安慰剂一致。

Immunovant believes that IMVT-1402 administered weekly can achieve steady reductions in IgG and further believes that steady reductions in IgG lowering are needed to avoid fluctuations in efficacy..

Immunovant认为，每周服用IMVT-1402可以稳定降低IgG，并进一步认为需要稳定降低IgG以避免疗效波动。。

About Immunovant, Inc.

关于Immunovant，Inc。

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

Immunovant，Inc.是一家临床阶段免疫学公司，致力于为自身免疫性疾病患者提供正常生活。作为抗FcRn技术的先驱，该公司正在开发创新的靶向疗法，以满足自身免疫性疾病患者复杂多变的需求。

For additional information on the Company, please visit www.immunovant.com..

有关该公司的更多信息，请访问www.immunovant.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as 'can,' “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” 'intend,' and other similar expressions are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》和其他联邦证券法中安全港条款的前瞻性声明。使用诸如“可以”、“可能”、“可能”、“会”、“会”、“应该”、“期望”、“相信”、“估计”、“设计”、“计划”、“打算”等词语，以及其他类似的表达方式，旨在识别前瞻性陈述。

Such forward looking statements include statements regarding Immunovant’s intellectual property portfolio; Immunovant’s belief regarding the impact to IgG with IMVT-1402 administered on a weekly basis; and potential benefits of IMVT-1402’s unique product attributes and potential best-in-class profile.

此类前瞻性声明包括有关Immunovant知识产权组合的声明；Immunovant相信IMVT-1402每周给药对IgG的影响；以及IMVT-1402独特的产品属性和潜在的同类最佳配置的潜在好处。

All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected.

所有前瞻性陈述均基于Immunovant管理层的估计和假设，尽管Immunovant认为这是合理的，但本质上是不确定的。所有前瞻性陈述都受到风险和不确定性的影响，这些风险和不确定性可能导致实际结果与Immunovant预期的结果存在重大差异。

Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, and general development progress; future clinical tr.

这些风险和不确定性包括：Immunovant可能无法保护或执行其知识产权；早期临床试验的初步结果或其他初步分析或结果可能无法预测最终试验结果或后期临床试验结果；临床试验数据的时间和可用性；与监管机构讨论的时间安排，以及监管提交和潜在批准；Immunovant候选产品的持续开发，包括开始额外临床试验的数量和时间；Immunovant的科学方法，临床试验设计，适应症选择和总体开发进展；未来的临床tr。

Contact:

联系人：

Chau Cheng, PhD, MBA

Chau Cheng，博士，MBA

Vice President, Investor Relations

投资者关系副总裁

Immunovant, Inc.

Immunovant公司。

info@immunovant.com

info@immunovant.com